Literature DB >> 27113004

Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange: When It Works and When It Does Not.

Tahir Mehmood1, Michelle Taylor2, Jeffrey L Winters3.   

Abstract

Thrombotic microangiopathies are a heterogeneous group of inherited and acquired disorders sharing a common clinical presentation of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. These disorders have been treated with plasma exchange (TPE) based on randomized controlled trials, which found this therapy to be effective in thrombotic thrombocytopenic purpura (TTP). For the remaining disorders, low- to very low-quality evidence exists for the use of TPE. When TPE is applied, the treatment regimen used for TTP is usually applied. There is a need for further evaluation of the role of TPE in the treatment of thrombotic microangiopathies other than TTP.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apheresis; Hemolytic uremic syndrome; Plasma exchange; Plasmapheresis; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Mesh:

Year:  2016        PMID: 27113004     DOI: 10.1016/j.hoc.2016.01.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

Review 1.  Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP).

Authors:  Jeffrey L Winters
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  TMA secondary to SLE: rituximab improves overall but not renal survival.

Authors:  Fangfang Sun; Xiaodong Wang; Wanlong Wu; Kaiwen Wang; Zhiwei Chen; Ting Li; Shuang Ye
Journal:  Clin Rheumatol       Date:  2017-08-30       Impact factor: 2.980

3.  Disease-modifying treatments for primary autoimmune haemolytic anaemia.

Authors:  Anthony Pak-Yin Liu; Daniel Kl Cheuk
Journal:  Cochrane Database Syst Rev       Date:  2021-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.